About Flagship Biosciences
Founded: 2009 Type: Privately Held Size: 51-200 employees
Flagship Biosciences, Inc. is the global leader in quantitative tissue image analysis solutions that help bio/pharmaceutical companies define their path to success. Flagship’s Computational Tissue Analysis (cTA™) platform provides the quantitative, contextual tissue interpretations necessary to make timely decisions, creating an indispensable partnership with bio/pharma companies in their development of novel drugs, especially in immuno-oncology (I/O). The proprietary cTA platform allows for the evaluation and interrogation of tissues using a patented cell-based approach to deliver the most biologically relevant quantification endpoints required for drug discovery, development and patient stratification.

Flagship offers its partners a continuous tissue image analysis technical pathway, from drug discovery through commercialization. Leveraging a unique combination of its technology platform, extensive expertise across multiple disciplines (e.g., pathology, biology, image analysis, software engineering), and an in-house CLIA lab, Flagship is developing quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics, including companion diagnostics (CDx).

Over 100 pharmaceutical, biotech, and medical device firms rely on Flagship’s technology for success. As the largest clinical tissue-image-analysis operation in the US, Flagship has completed over 400 projects since 2009.

Visit flagshipbio.com for more information